High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial

We conducted a prospective, multicenter, randomized, controlled clinical trial to compare the efficacy and safety of high‐dose dexamethasone (HD‐DXM) plus recombinant human thrombopoietin (rhTPO), vs HD‐DXM alone in newly diagnosed adult immune thrombocytopenia (ITP) patients. Enrolled patients were...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2020-12, Vol.95 (12), p.1542-1552
Main Authors: Yu, Yafei, Wang, Miaomiao, Hou, Yu, Qin, Ping, Zeng, Qingshu, Yu, Wenzheng, Guo, Xinhong, Wang, Jingxia, Wang, Xiaomin, Liu, Guoqiang, Chu, Xiaoxia, Yang, Lan, Feng, Ying, Zhou, Fang, Sun, Zhaogang, Zhang, Mei, Wang, Xin, Wang, Zhencheng, Ran, Xuehong, Zhao, Hongguo, Wang, Lei, Zhang, Haiyan, Bi, Kehong, Li, Daqi, Yuan, Chenglu, Xu, Ruirong, Wang, Yili, Zhou, Yuhong, Peng, Jun, Liu, Xin‐guang, Hou, Ming
Format: Article
Language:English
Subjects:
Dexamethasone
Hematology
Idiopathic thrombocytopenic purpura
Immunosuppressive agents
Patients
Steroids
Thrombocytopenia
Thrombopoietin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted a prospective, multicenter, randomized, controlled clinical trial to compare the efficacy and safety of high‐dose dexamethasone (HD‐DXM) plus recombinant human thrombopoietin (rhTPO), vs HD‐DXM alone in newly diagnosed adult immune thrombocytopenia (ITP) patients. Enrolled patients were randomly assigned to receive DXM plus rhTPO or DXM monotherapy. Another 4‐day course of DXM was repeated if response was not achieved by day 10 in both arms. One hundred patients in the HD‐DXM plus rhTPO arm and 96 patients in the HD‐DXM monotherapy arm were included in the full analysis set. So, HD‐DXM plus rhTPO resulted in a higher incidence of initial response (89.0% vs 66.7%, P 
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.25989